Related references
Note: Only part of the references are listed.Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing
Wibowo Arindrarto et al.
LEUKEMIA (2021)
Clonal competition within complex evolutionary hierarchies shapes AML over time
Carl Sanden et al.
NATURE COMMUNICATIONS (2020)
Modulation of FLT3 signal transduction through cytoplasmic cysteine residues indicates the potential for redox regulation
Annette Boehmer et al.
REDOX BIOLOGY (2020)
Impact of FLT3-ITD length on prognosis of acute myeloid leukemia
Song-Bai Liu et al.
HAEMATOLOGICA (2019)
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Donia M. Moujalled et al.
LEUKEMIA (2019)
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
Peter van Galen et al.
CELL (2019)
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
Paolo Sportoletti et al.
LEUKEMIA (2019)
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia
Xuejie Jiang et al.
CLINICAL CANCER RESEARCH (2018)
FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Emily Y. Jen et al.
CLINICAL CANCER RESEARCH (2018)
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
Bettina Wingelhofer et al.
LEUKEMIA (2018)
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia
Jessica C. Petrov et al.
LEUKEMIA (2018)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Homing in: Mechanisms of Substrate Targeting by Protein Kinases
Chad J. Miller et al.
TRENDS IN BIOCHEMICAL SCIENCES (2018)
A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia
Wojciech Czardybon et al.
Oncotarget (2018)
Acute myeloid leukemia: 2019 update on risk-stratification and management
Elihu H. Estey
AMERICAN JOURNAL OF HEMATOLOGY (2018)
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Regina Jitschin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia
Masahiro Sakaguchi et al.
BLOOD ADVANCES (2018)
Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3ITD AML with Secondary Acquired Mutations
Kotoko Yamatani et al.
BLOOD (2018)
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
Takeshi Yamaura et al.
BLOOD (2018)
MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia
Xiaolu Zhang et al.
ANNALS OF HEMATOLOGY (2018)
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Joan Montero et al.
CELL DEATH AND DIFFERENTIATION (2018)
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Jerry M. Adams et al.
CELL DEATH AND DIFFERENTIATION (2018)
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Steven Knapper et al.
BLOOD (2017)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia
Jay L. Patel et al.
LEUKEMIA RESEARCH (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
FLT3 inhibitors: clinical potential in acute myeloid leukemia
Marie-Anne Hospital et al.
ONCOTARGETS AND THERAPY (2017)
FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway
Keigo Okada et al.
Oncotarget (2017)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies
J. Kyle Bruner et al.
CANCER RESEARCH (2017)
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Katherine Tarlock et al.
CLINICAL CANCER RESEARCH (2017)
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Catherine C. Smith et al.
BLOOD (2017)
An update of current treatments for adult acute myeloid leukemia
Herve Dombret et al.
BLOOD (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Acute myeloid leukemia: a comprehensive review and 2016 update
I. De Kouchkovsky et al.
BLOOD CANCER JOURNAL (2016)
The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor
Nadine Sandhoefer et al.
SCIENTIFIC REPORTS (2016)
Risk Stratification and Implications for Therapy
Michael L. Wang et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length
Y. Kim et al.
BLOOD CANCER JOURNAL (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
Ayako Nogami et al.
ONCOTARGET (2015)
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
Genevra Pillinger et al.
SCIENTIFIC REPORTS (2015)
Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature
Pierre Cauchy et al.
CELL REPORTS (2015)
Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
Julie A. Zorn et al.
PLOS ONE (2015)
4-Hydroxy-nonenal-A Bioactive Lipid Peroxidation Product
Rudolf J. Schaur et al.
BIOMOLECULES (2015)
Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
Hong Wu et al.
ACS CHEMICAL BIOLOGY (2014)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia
Hee Kyu Lee et al.
BLOOD (2014)
Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
Yesid Alvarado et al.
CANCER (2014)
Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
S. Nag et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?
Carolyn S. Grove et al.
DISEASE MODELS & MECHANISMS (2014)
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
Matthew S. Davids et al.
FUTURE ONCOLOGY (2014)
Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia
R. B. Walter et al.
LEUKEMIA (2014)
Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia
Hanna Janke et al.
PLOS ONE (2014)
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A. Ehninger et al.
BLOOD CANCER JOURNAL (2014)
Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML
D. L. Stirewalt et al.
BLOOD CANCER JOURNAL (2014)
Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia
Brian Parkin et al.
BLOOD (2013)
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia
Sabrina Opatz et al.
BLOOD (2013)
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
Eric I. Zimmerman et al.
BLOOD (2013)
Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling
Paul S. Hole et al.
BLOOD (2013)
Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
Sharyn D. Baker et al.
CLINICAL CANCER RESEARCH (2013)
Detection of Minor Clones With Internal Tandem Duplication Mutations of FLT3 Gene in Acute Myeloid Leukemia Using Delta-PCR
Katie Beierl et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2013)
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
C. Albers et al.
LEUKEMIA (2013)
Multiple glutathione disulfide removal pathways mediate cytosolic redox homeostasis
Bruce Morgan et al.
NATURE CHEMICAL BIOLOGY (2013)
Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
Karthika Natarajan et al.
PLOS ONE (2013)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/PTPRJ
Rinesh Godfrey et al.
BLOOD (2012)
Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3
De-Chen Lin et al.
BLOOD (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
Stefan P. Glaser et al.
GENES & DEVELOPMENT (2012)
Suppressor of Cytokine Signaling 6 (SOCS6) Negatively Regulates Flt3 Signal Transduction through Direct Binding to Phosphorylated Tyrosines 591 and 919 of Flt3
Julhash U. Kazi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
Michele McTigue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
S. Kasper et al.
BLOOD CANCER JOURNAL (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex
Kenneth Verstraete et al.
BLOOD (2011)
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato et al.
BLOOD (2011)
Regulation of protein tyrosine phosphatases by reversible oxidation
Arne Ostman et al.
JOURNAL OF BIOCHEMISTRY (2011)
Further activation of FLT3 mutants by FLT3 ligand
R. Zheng et al.
ONCOGENE (2011)
Protein kinases: evolution of dynamic regulatory proteins
Susan S. Taylor et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Receptor tyrosine kinase transmembrane domains Function, dimer structure and dimerization energetics
Edwin Li et al.
CELL ADHESION & MIGRATION (2010)
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor
Frank Breitenbuecher et al.
BLOOD (2009)
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation
Goichi Yoshimoto et al.
BLOOD (2009)
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Frank Breitenbuecher et al.
BLOOD (2009)
Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality
Dirk Schmidt-Arras et al.
BLOOD (2009)
Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia
Soheil Meshinchi et al.
CLINICAL CANCER RESEARCH (2009)
Ectodomain Shedding of FLT3 Ligand Is Mediated by TNF-α Converting Enzyme
Keisuke Horiuchi et al.
JOURNAL OF IMMUNOLOGY (2009)
Lestaurtinib: a multi-targeted FLT3 inhibitor
Amir T. Fathi et al.
EXPERT REVIEW OF HEMATOLOGY (2009)
Structural and numerical variation of FLT3/ITD in pediatric AML
Soheil Meshinchi et al.
BLOOD (2008)
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML
Annahita Sallmyr et al.
BLOOD (2008)
Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival
Yoshikane Kikushige et al.
JOURNAL OF IMMUNOLOGY (2008)
Prognostic relevance of FLT3-TKD mutations in AML:: the combination matters -: an analysis of 3082 patients
Ulrike Bacher et al.
BLOOD (2008)
Hematopoietic developmental pathways: on cellular basis
H. Iwasaki et al.
ONCOGENE (2007)
Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53
Jonathan M. Irish et al.
BLOOD (2007)
FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248)
M. M. Schittenhelm et al.
LEUKEMIA (2006)
Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation
Amy D. Hartman et al.
EXPERIMENTAL HEMATOLOGY (2006)
Constitutively activated FLT3 phosphorylates BAD partially through Pim-1
Kyu-Tae Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2
Elke Heiss et al.
BLOOD (2006)
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD
Jennifer L. Rocnik et al.
BLOOD (2006)
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML
C Reindl et al.
BLOOD (2006)
IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples
O Piloto et al.
CANCER RESEARCH (2006)
D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias
S Schnittger et al.
GENES CHROMOSOMES & CANCER (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation
CH Brandts et al.
CANCER RESEARCH (2005)
Functional expression, purification, and characterization of human Flt3 ligand in the Pichia pastoris system
YL Zhang et al.
PROTEIN EXPRESSION AND PURIFICATION (2005)
Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth
B Williams et al.
LEUKEMIA (2005)
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
M Levis et al.
BLOOD (2005)
Features of selective kinase inhibitors
ZA Knight et al.
CHEMISTRY & BIOLOGY (2005)
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice
O Piloto et al.
CANCER RESEARCH (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression
R Zheng et al.
BLOOD (2004)
Heterogeneous patterns of FLT3 ASP835 mutations in relapsed de novo acute myeloid leukemia:: A comparative analysis of 120 paired diagnostic and relapse bone marrow samples
LY Shih et al.
CLINICAL CANCER RESEARCH (2004)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
JR Jiang et al.
BLOOD (2004)
Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia
J Cools et al.
CANCER RESEARCH (2004)
Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
NK Damle
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
M Levis et al.
BLOOD (2004)
Structure and regulation of Src family kinases
TJ Boggon et al.
ONCOGENE (2004)
Monoclonal antibody therapeutics and apoptosis
DL Ludwig et al.
ONCOGENE (2003)
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes
TJ Ley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia
Y Minami et al.
BLOOD (2003)
Production of PtdInsP(3) at endomembranes is triggered by receptor endocytosis
M Sato et al.
NATURE CELL BIOLOGY (2003)
The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras
C Jiménez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation
LD Cripe et al.
LEUKEMIA (2002)
Phosphotyrosine-binding domains in signal transduction
MB Yaffe
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
LM Kelly et al.
BLOOD (2002)
Origin of alternative splicing by tandem exon duplication
FA Kondrashov et al.
HUMAN MOLECULAR GENETICS (2001)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Genomic structure of human FLT3:: Implications for mutational analysis
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells
HJ McKenna et al.
BLOOD (2000)
Expression of Flt3-ligand by the endothelial cell
A Solanilla et al.
LEUKEMIA (2000)
Share Paper
